ATE110965T1 - Impfstoffe gegen hämophilus influenzae. - Google Patents

Impfstoffe gegen hämophilus influenzae.

Info

Publication number
ATE110965T1
ATE110965T1 AT90905112T AT90905112T ATE110965T1 AT E110965 T1 ATE110965 T1 AT E110965T1 AT 90905112 T AT90905112 T AT 90905112T AT 90905112 T AT90905112 T AT 90905112T AT E110965 T1 ATE110965 T1 AT E110965T1
Authority
AT
Austria
Prior art keywords
influencae
extracting
vaccines against
protein
influenzae
Prior art date
Application number
AT90905112T
Other languages
English (en)
Inventor
Bruce A Green
Gary W Zlotnick
Original Assignee
Praxis Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biolog Inc filed Critical Praxis Biolog Inc
Application granted granted Critical
Publication of ATE110965T1 publication Critical patent/ATE110965T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT90905112T 1989-03-09 1990-03-09 Impfstoffe gegen hämophilus influenzae. ATE110965T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32097189A 1989-03-09 1989-03-09

Publications (1)

Publication Number Publication Date
ATE110965T1 true ATE110965T1 (de) 1994-09-15

Family

ID=23248627

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94100492T ATE195076T1 (de) 1989-03-09 1990-03-09 Verfahren zur isolierung von haemopnilus influenzae protein-e
AT90905112T ATE110965T1 (de) 1989-03-09 1990-03-09 Impfstoffe gegen hämophilus influenzae.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94100492T ATE195076T1 (de) 1989-03-09 1990-03-09 Verfahren zur isolierung von haemopnilus influenzae protein-e

Country Status (13)

Country Link
US (4) US5601831A (de)
EP (2) EP0462210B1 (de)
JP (1) JP2955014B2 (de)
KR (1) KR100188323B1 (de)
AT (2) ATE195076T1 (de)
AU (1) AU648251B2 (de)
CA (1) CA2047681C (de)
DE (2) DE69012318T2 (de)
DK (2) DK0462210T3 (de)
ES (2) ES2063965T3 (de)
FI (1) FI914241A0 (de)
NO (1) NO913518L (de)
WO (1) WO1990010458A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340888C (en) * 1988-09-01 2000-02-01 Algis Anilionis Vaccines and diagnostic assays for haemophilus influenzae
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
WO1993008290A1 (en) * 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
DK0624376T3 (da) * 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
JPH11508225A (ja) * 1995-04-17 1999-07-21 ヘンリー エム．ジャクソン ファンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン 細菌のリポ蛋白質を用いた多糖類に対する免疫応答の誘導および増強
AR003125A1 (es) * 1995-06-01 1998-07-08 Astra Ab Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
GB9513074D0 (en) * 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
WO2002089839A1 (en) * 2001-05-03 2002-11-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US20040126381A1 (en) * 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
AU749810B2 (en) * 1997-11-12 2002-07-04 Basilea Pharmaceutica Ag Treatment of T-helper cell type 2 mediated immune diseases
US6255050B1 (en) * 1998-05-22 2001-07-03 Lorne Park Research, Inc. Dynamic hybridization system
EP1189935B1 (de) 1999-06-25 2008-10-22 Wyeth Holdings Corporation Extraktion von integralen membranproteinen
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
US6391313B1 (en) * 1999-07-15 2002-05-21 Aventis Pasteur Limited Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
JP2003507433A (ja) * 1999-08-20 2003-02-25 ザ ゼネラル ホスピタル コーポレーション 敗血症治療において治療に用いる対象としての外膜タンパク質ａ、ペプチドグリカン関連リポタンパク質およびムレインリポタンパク質
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
WO2002009748A1 (en) * 2000-07-31 2002-02-07 Yale University Innate immune system-directed vaccines
GB0025486D0 (en) * 2000-10-17 2000-11-29 Smithkline Beecham Biolog Novel compounds
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US6834384B2 (en) * 2001-03-14 2004-12-21 General Instrument Corporation Methods and apparatus for upgrading firmware in an embedded system
KR20080078717A (ko) * 2001-06-07 2008-08-27 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
EP1404368B1 (de) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutantenformen von cholera holotoxin als adjuvans
AU2002310760A1 (en) * 2001-06-12 2002-12-23 Glaxosmithkline Biologicals S.A. Proteins derived from non-typable haemophilus influenzae (nthi) strain
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
MXPA04008890A (es) * 2002-03-15 2005-10-18 Wyeth Corp Mutantes de la proteina p4 de haemophilus influenzae no tipicable con actividad enzimatica reducida.
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425855A1 (de) 2005-04-08 2012-03-07 Wyeth LLC Multivalente Pneumokokken-Polysaccharidproteinkonjugatzusammensetzung
KR20070047455A (ko) * 2005-11-02 2007-05-07 삼성에스디아이 주식회사 전자 방출 표시 디바이스
ES2534332T3 (es) * 2006-03-07 2015-04-21 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
PL1915913T3 (pl) * 2006-10-23 2016-06-30 Nestec Sa Modulowanie smaku oraz aromatu w mlecznych produktach poprzez biotransformację
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20110294143A1 (en) * 2009-01-07 2011-12-01 Otsuka Pharmaceutical Co., Ltd. Method for detecting all haemophilus influenzae
SI3246044T2 (sl) 2010-08-23 2024-06-28 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
ES2585328T5 (es) 2010-09-10 2022-12-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
EP3041502A2 (de) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
IL267733B2 (en) 2017-01-31 2023-10-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220717A (en) * 1977-12-22 1980-09-02 American Cyanamid Company Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4220722A (en) 1978-02-10 1980-09-02 Syva Company Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4661347A (en) * 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4873090A (en) * 1985-03-27 1989-10-10 Broncostat Pty. Limited Non-adjuvenated vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JP2534529B2 (ja) * 1986-07-24 1996-09-18 ブリティシュ・テレコミュニケ−ションズ・パブリック・リミテッド・カンパニ 放射発生器
US5173294A (en) * 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
AU623353B2 (en) * 1987-12-10 1992-05-14 Board Of Regents, The University Of Texas System Methods and compositions for the production of haemophilus influenzae type b major outer membrane protein antigens

Also Published As

Publication number Publication date
US6420134B1 (en) 2002-07-16
DE69012318D1 (de) 1994-10-13
DE69033600D1 (de) 2000-09-07
ES2150450T3 (es) 2000-12-01
EP0462210A1 (de) 1991-12-27
NO913518L (no) 1991-10-29
US5780601A (en) 1998-07-14
JP2955014B2 (ja) 1999-10-04
NO913518D0 (no) 1991-09-06
EP0606921A1 (de) 1994-07-20
FI914241A0 (fi) 1991-09-09
DK0462210T3 (da) 1994-10-10
EP0462210B1 (de) 1994-09-07
KR100188323B1 (ko) 1999-06-01
CA2047681A1 (en) 1990-09-10
ES2063965T3 (es) 1995-01-16
AU648251B2 (en) 1994-04-21
AU5332690A (en) 1990-10-09
US5955580A (en) 1999-09-21
US5601831A (en) 1997-02-11
DE69033600T2 (de) 2001-04-05
JPH07508972A (ja) 1995-10-05
WO1990010458A1 (en) 1990-09-20
ATE195076T1 (de) 2000-08-15
CA2047681C (en) 2000-02-01
DK0606921T3 (da) 2000-09-04
EP0606921B1 (de) 2000-08-02
DE69012318T2 (de) 1995-03-09

Similar Documents

Publication Publication Date Title
ATE110965T1 (de) Impfstoffe gegen hämophilus influenzae.
PT82610B (pt) Processo para a preparacao de tiazolidino-dionas hipoglicemicas
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
IT8619684A0 (it) Preparato di acido ialuronico chimicamente modificato e metodo per recuperarlo da tessuti animali.
CA2005291A1 (en) Feline infectious peritonitis virus diagnostic tools
NO871333L (no) Kinolin-3-karboksylsyrederivater, fremgangsmaate til fremstilling og anvendelse derav.
DE3852140D1 (de) Produktion von Proteinen in aktiven Formen.
LV5765A4 (lv) (S)-(-)-1-propil-2',6'-pipekoloksilidida hidrohlorida monohidrats ta iegusanas metode un to satuross farmaceitisks preparats
DE3783199D1 (de) Verfahren zur herstellung von 4,4' diaminodiphenylmethan und derivaten davon.
WO1996019498A3 (en) T cell stimulating protein of pestivirus
DE3678487D1 (de) Verfahren zur herstellung von 6-amino-3-hydrazino-pyridazinderivaten.
LV10626A (lv) Peptidi
JPS53127808A (en) Preparation of human albumin
HUT41632A (en) Process for preparing agents for the enhancement of protein absorption
DE3763312D1 (de) Verfahren zur herstellung von hexaalkyldisilan.
DK44487D0 (da) 1-oe3-(2-hydroxy-3-alkylaminopropoxy)-2-thienylaa-3-phenyl-1-propanon eller syreadditionssalt deraf samt fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende en saadan forbindelse
IL78343A0 (en) Newcastle's disease virus(ndv)vaccine and method for the application thereof
ATE93725T1 (de) Pharmazeutische praeparate, die eine waesserige loesung eines pyranoquinolins enthalten.
AU583464C (en) Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues.
JPS5559146A (en) Isolation of phenylalanine
MX9709525A (es) Vacunas de virus sincicial respiratorio de acido nucleico.
CS521986A1 (en) Method of dimethylamine's aqueous solution preparation
IT8622750A0 (it) Procedimento per la preparazione di idrolizzati proteici enzimatici solubili in ambiente acido ed idrolizzati cosi' ottenuti.
IL81475A0 (en) Newcastle disease virus(ndv)vaccine and method for the application thereof
ATE83767T1 (de) Verfahren zur herstellung von 4,4' diaminodiphenylmethan und derivaten davon.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time